In this short review, we discuss apolipoprotein B100 and the assembly of very low-density lipoproteins. In particular, we address the nature and importance of co-and posttranslational degradation of apolipoprotein B100 during the assembly process. We also provide a short historical background to the development of the current model for the degradation of apolipoprotein B100. (Arterioscler Thromb Vasc Biol. 2012;32:1334-1338) 
History of Discovery History of discovery
A polipoprotein B (apoB) is a large hydrophobic protein that plays an essential role in the formation of triacylglycerol-rich lipoproteins. It is unique among apolipoproteins in that it is nonexchangeable and therefore remains with the lipoprotein particle from the time it is formed in the liver or intestine until it is removed and catabolized through cell uptake. All other plasma apolipoproteins are exchangeable, moving between different lipoproteins as they circulate and remodel in the plasma.
There are 2 apoB species: apoB100 and apoB48. The fulllength apoB (apoB100) is formed in the liver where it assembles very low-density lipoproteins (VLDL). ApoB48, which corresponds to the N-terminal 48% of apoB100, is formed in the intestine and is essential for the assembly of chylomicrons. This short review will focus on apoB100 in the formation of VLDL.
ApoB100 is the ligand for the low-density lipoprotein (LDL) receptor, 1 and elevated plasma levels of LDL-apoB100 are strongly associated with increased risk of coronary artery disease. The protein is directly involved in the retention of LDL with the arterial wall because the interaction involves an ionic interaction between basic amino acids in apoB100 and negatively charged sulfate groups on the artery wall proteoglycans. 2 This mechanism is the basis of the response-toretention hypothesis for the development of atherosclerosis. 3 Despite its clinical importance, apoB100 was for many years an enigma to scientists, mainly because of its large size, insolubility, and tendency to aggregate. A breakthrough was the cloning of the gene in the mid-1980s, which gave us the amino acid sequence and tools to determine its expression and carry out more in-depth analyses of its structure and biology. 4
intracellular Transfer of ApoB100 and Formation of Vldl
For many years, the understanding of the biosynthesis of VLDL was based on descriptive immunoelectron microscopy studies from the mid-1970s. 5 To further our understanding of the synthesis and intracellular transport of apoB100, we performed kinetic studies using pulse-chase methodology with 35 S-methionine in the human hepatocyte cell line HepG2. [6] [7] [8] After a lag phase of about 30 minutes, apoB100 could be detected in the medium without any change in apparent molecular weight, indicating that no posttranslational proteolytic processing occurred. To gain further insight into the intracellular transport and secretion of apoB100, we used subcellular fractionation in combination with pulse-chase methodology. This enabled us to study the residence kinetics of apoB100 in the endoplasmic reticulum (ER) and the Golgi apparatus, as well as its transfer between the 2 compartments. We found that the apoB100 radioactivity increased rapidly in the ER membrane during the first 5 to 10 minutes and reached its peak in the ER and Golgi lumina after 20 and 40 minutes of chase, respectively. 7 We also characterized the apoB100-containing lipoproteins in the secretory pathway and identified 3 different species (fractions I, II, and III). 8 The sizes and densities of the particles in fractions II and III were similar to the major apoB100containing lipoproteins secreted into the medium (VLDL assembly is defective in HepG2 cells, resulting in the secretion of both immature triglyceride-poor LDL-sized particles and fully lipidated VLDL particles). 9 Fraction I particles (later called pre-VLDL) had the density of high-density lipoprotein particles and were not secreted from the cells. 8 Pulse-chase experiments showed a redistribution of the apoB100 radioactivity from fraction I to II over time. The interpretation of these results was unclear, and we speculated that fraction I could either be a precursor form of mature lipidated lipoprotein particles or sorted to degradation. The relationship between fraction I and the ER membrane was also unclear. 8 disappearance of apoB100 from the ER membrane was much higher than the rate of apoB100 secretion. This discrepancy was initially difficult to understand and we performed numerous control experiments to rule out methodological recovery problems as the explanation. We also ruled out the possibility that the discrepancy was caused by rapid cellular uptake of newly secreted apoB100-containing lipoproteins. Therefore, the only explanation for the discrepancy was that a portion of the intracellular pool of apoB100 diverged from the secretory process to undergo posttranslational degradation. 7 In parallel with others, we studied the regulation of VLDL and showed that physiological concentrations of oleic acid complexed to albumin in the culture medium of HepG2 cells caused a 3-to 4-fold increase in apoB100 secretion 8, 11 without alteration of apoB mRNA levels. 8, 12 These results indicated that lipids could rescue apoB100 from posttranslational degradation; thus, apoB100 appeared to be continuously synthesized, and apoB100 that was not used in VLDL formation was sorted to posttranslational degradation.
The existence of a posttranslational degradation pathway for apoB100 was originally suggested by our group in 1986. 7 Several other groups were working in the same area, and our results were rapidly verified and shown to also occur in rats and cynomolgus monkeys. [12] [13] [14] [15] [16] [17] [18] Of particular importance were the studies by Roger Davis and colleagues who showed that a significant portion of de novo-synthesized apoB that was lost from the cells could not be accounted for as secreted protein in primary rat hepatocytes. 13 His group further demonstrated that apoB was present on the cytosolic side of the secretory pathway, thus showing that there were 2 pools of apoB: 1 that was translocated through the ER and 1 that was not. 14 This was a rather provocative result at the time. Davis also showed that the 2 pools had different fates: the pool that was translocated formed lipoproteins, whereas the other pool was sorted to degradation.
The concept of a posttranslational degradation of apoB100 was at the time questioned because it "seemed unphysiological that cells should spend energy to synthesize proteins that were rapidly sorted to degradation" [a reviewer's comment]. Furthermore, the results also contradicted earlier studies by Siuta-Mangano et al 19 who used pulse-chase experiments to show that chick hepatocytes displayed a quantitative recovery of apoB in the culture medium. The finding that apoB was constitutively expressed was also disappointing for many scientists because they had hoped for a transcriptional regulation of apoB100 that could explain hyperlipidemia and premature atherosclerosis, and serve as a framework for developing strategies for the prevention of cardiovascular diseases.
Interestingly, of central importance for these studies was the relationship between apoB100 and the ER membrane. Owing to the insolubility of apoB100 in water and its propensity to interact nonspecifically with membranes during the preparation, we long thought that the protein was integrated into the ER membrane (similar to the integral membrane proteins) and that VLDL was formed from the ER membrane. However, the observation that apoB100 lacked long hydrophobic sequences but rather contained amphipathic structures (-helices as well as -sheets) argued against such a mechanism, and the field was divided into those in favor of and those against integration into the ER membrane. In later studies, we showed that the proposed integration of apoB into the ER membrane was an artifact and that apoB100 was cotranslationally lipidated to form lipoproteins. 20 We also developed methodology that allowed us to extract most (88%) of the ER membrane-associated apoB100, but not integral membrane proteins. The major effect of this method was to increase the recovery of apoB100 in immature nascent pre-VLDL particles, suggesting that the majority of the membrane-associated form of apoB100 consisted of partially lipidated nascent VLDL particles (pre-VLDL). 21
sorting Out the degradation Pathways
Several laboratories over the past 20 years have shown that the degradation of apoB100 is accomplished by both proteasomal and nonproteasomal pathways and that each type of degradation is regulated by 1 metabolic factors.
Proteasomal Degradation
Fisher and Ginsberg made a seminal contribution to our understanding of the proteosomal-mediated ER-associated degradation of apoB100. They first demonstrated that apoB100 starts to loop out on the cytosolic side of the ER to interact with the heat shock protein 70 and the proteasomes when the N-terminal sequence is still attached to the ER membrane and its translocon. 22 This loop out and degradation could be overcome by increased triglyceride biosynthesis. 22 These observations were in agreement with the observation by Davis et al 14 as well as with our own results. 23 Interestingly, HIV protease inhibitors, agents that cause a dyslipidemia characterized by increased VLDL levels, 24 are inhibitors of the proteasome. 25 Increased protection of nascent apoB from degradation and, in the presence of oleic acid, increased secretion of apoB lipoproteins have been observed in a variety of human and rodent hepatic cell types after treatment with HIV protease inhibitors. 26 These data support a significant role for proteasomal degradation in the in vivo regulation of apoB secretion in mammals.
Nonproteasomal Degradation
Fisher et al 27 demonstrated that the posttranslational degradation of apoB100 also occurs by a previously unknown mechanism in a compartment separate from the rough ER, which is known as post-ER presecretory proteolysis (PERPP). In a series of elegant articles, they unraveled the mechanism for PERPP, which can destroy up to 90% of newly synthesized apoB. [27] [28] [29] [30] [31] PERPP stimulation induces aggregation of apoBcontaining lipoproteins, which are then sorted to degradation though the autophagy pathway. [29] [30] [31] PERPP is stimulated under a number of common metabolic circumstances 32 and may explain why diets rich in polyunsaturated fatty acids result in lower plasma levels of VLDL. 30
Degradation After ApoB100 Secretion
In addition to co-and posttranslational degradation of apoB100, Williams et al 33 demonstrated that degradation also occurs after apoB100 secretion in vitro. They identified an unstirred water layer around the outside of the plasma membrane from where apoB-containing lipoproteins are taken up via the LDL receptor. 33 However, in vivo studies in mice or humans have not, overall, shown a relationship between LDL receptor activity and apoB secretion.
Assembly and Degradation: Where Do They Meet?
The assembly of VLDL thus involves pre-VLDL, which is not secreted, and mature lipoproteins that transfer through the secretory pathway to be secreted. The mature forms of VLDL are the triglyceride-poor VLDL 2 and triglyceride-rich VLDL 1 . 34 Below, we will briefly recapitulate the assembly process and point out where the sorting to degradation could occur.
The assembly process starts when the growing apoB100 polypeptide is cotranslationally lipidated by microsomal triglyceride transfer protein in the lumen of the ER (Figure) . Failure in this process results in proteosomal-mediated degradation. 31 This is the first quality control and the degradation that occurs closest to the biosynthesis of the protein (Figure) .
Pre-VLDL is the next target for degradation. This is by definition a posttranslational degradation. Pre-VLDL is retained and degraded unless it is converted to VLDL 2 (or at least an LDL-sized particle). 8, 34 The C-terminal region of apoB100 seems to be important for the presence/retention of pre-VLDL in the secretory pathway, 34 and it is plausible that this region mediates the sorting of pre-VLDL to degradation (tentatively by autophagy). Moreover, pre-VLDL is highly associated with chaperone proteins such as glucose-regulated protein 78 and protein disulfide isomerase. It is therefore possible that regions in the C-terminus of apoB100 sense the degree of lipidation and anchor the partially lipidated particle to chaperones, which retain the particle in the ER. Once the level of lipidation is sufficient to allow apoB100 to fit on the particle and the C-terminus to fold correctly, the chaperones dissociate and the particle can transfer out of the ER. Thus, the primordial lipoprotein is either retained in the cell and degraded or further lipidated to form VLDL. 34 The lipoprotein can be secreted once the precursor has been lipidated sufficiently so that apoB100 can fold correctly on the particle. This occurs when it has a diameter of ≈300Å. 8 The formed VLDL 2 particle can acquire more lipids in the Golgi apparatus to become the triglyceride-rich VLDL 1 . 34 These mature particles in the later part of the secretory pathway also seem to be guarded by a quality control system coupled to autophagy [29] [30] [31] (Figure) .
Figure.
The assembly of very low-density lipoprotein (VLDL) and the sorting of apolipoprotein B (apoB) to degradation. The assembly process starts when apoB100 is translocated to the lumen of the endoplasmic reticulum (ER) and interacts with microsomal triglyceride transfer protein (MTP). ApoB100 that does not interact with MTP or is not sufficiently lipidated is sorted to proteasomal degradation. MTP-driven lipidation gives rise to pre-VLDL which is retained in the ER through interaction with chaperones if not further processed to become VLDL 2 . Pre-VLDL that is not converted to a mature lipoprotein will be sorted to posttranslational degradation (perhaps through autophagy). VLDL 2 exits the ER and is either converted to VLDL 1 in the Golgi apparatus through the addition of triglycerides (TG) or secreted. Lipoproteins that aggregate or denature during the transport through the secretory pathway are likely sorted to autophagy by post-ER presecretory proteolysis (PERPP).
Thus, the overall process is extensive and provides remarkable quality control of apoB100 secretion, but why have we developed so much degradative control? A potential explanation is that it allows rapid and dynamic regulation of VLDL production by lipid availability and metabolic perturbations. In what appears to be a normal response to diets rich in polyunsaturated fatty acids, which are readily peroxidized, apoB may become oxidatively modified. The late-stage PERPP quality control may be important to protect the liver from potentially toxic aggregates and prevent the export of lipid peroxides on VLDL to triglyceride-consuming, but oxidantsensitive, tissues in the periphery, such as cardiac muscle.
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A few days before New Year 2012, we received the totally unexpected and tragic news that Sven-Olof Olofsson had passed away at home at the age of 64. Sven-Olof was a highly regarded, respected, and muchloved colleague: always enthusiastic and full of ideas, always wise and compassionate, but also with high standards-not least for himself. In terms of quality of research, he was incorruptible and never sought any shortcuts. Sven-Olof loved to discuss science, and his door was always open to his laboratory members, colleagues, and young researchers who wanted to discuss science or who sought advice and support, and any meetings often ended with his chuckling laugh. His contagious passion for science attracted many PhD students, and he was always generous with his time for scientific guidance. He was also extraordinarily supportive and generous to his former PhD students, and was most proud when his former PhD students succeeded in their careers.
When Sven-Olof was invited to write this historical review, he was somewhat perturbed because it should have a personal touch. He said "I'm not an author, I can only write science." However, he was honored to write it and at an early stage decided to dedicate it to his friend Roger Davis. Their friendship started in 1988 after the publication by Borchardt and Davis in 1987. 13 Roger wrote in that paper that "our results show for the first time that a significant portion of the de novo synthesized apoB that was lost from the cells could not be accounted for as secreted protein." Sven-Olof was initially upset because his group published similar data 1 year before 7 (Sven-Olof later admitted that it was easy to miss it in his publication because it is only briefly mentioned), so he decided to contact Roger and wrote a letter where he proposed that they "should sit down over a bear [sic] to discuss VLDL assembly." This developed into a close friendship.
Sven-Olof was a bright but modest and soft-spoken gentleman with an exceptional personality and lovely sense of humor. His memory will stand as a figure of tremendous stature in the field of lipidology. 
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